These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 26297992)

  • 1. Growth factors mediated cell signalling in prostate cancer progression: Implications in discovery of anti-prostate cancer agents.
    Joshi G; Singh PK; Negi A; Rana A; Singh S; Kumar R
    Chem Biol Interact; 2015 Oct; 240():120-33. PubMed ID: 26297992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review.
    Ozkan EE
    Mol Cell Endocrinol; 2011 Sep; 344(1-2):1-24. PubMed ID: 21782884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the relaxin hormonal pathway in prostate cancer.
    Neschadim A; Summerlee AJ; Silvertown JD
    Int J Cancer; 2015 Nov; 137(10):2287-95. PubMed ID: 25043063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth factor and signaling pathways and their relevance to prostate cancer therapeutics.
    Wozney JL; Antonarakis ES
    Cancer Metastasis Rev; 2014 Sep; 33(2-3):581-94. PubMed ID: 24402967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting continued androgen receptor signaling in prostate cancer.
    Massard C; Fizazi K
    Clin Cancer Res; 2011 Jun; 17(12):3876-83. PubMed ID: 21680543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. microRNA and non-canonical TGF-β signalling: implications for prostate cancer therapy.
    Ottley E; Gold E
    Crit Rev Oncol Hematol; 2014 Oct; 92(1):49-60. PubMed ID: 24985060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth factor signalling in prostatic growth: significance in tumour development and therapeutic targeting.
    Reynolds AR; Kyprianou N
    Br J Pharmacol; 2006 Feb; 147 Suppl 2(Suppl 2):S144-52. PubMed ID: 16465179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGF signalling in prostate cancer cell lines is inhibited by a high expression level of the endocytosis protein REPS2.
    Oosterhoff JK; Kühne LC; Grootegoed JA; Blok LJ
    Int J Cancer; 2005 Feb; 113(4):561-7. PubMed ID: 15455380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of fibroblast growth factors and their receptors in prostate cancer.
    Kwabi-Addo B; Ozen M; Ittmann M
    Endocr Relat Cancer; 2004 Dec; 11(4):709-24. PubMed ID: 15613447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin-Like Growth Factor (IGF) family and prostate cancer.
    Gennigens C; Menetrier-Caux C; Droz JP
    Crit Rev Oncol Hematol; 2006 May; 58(2):124-45. PubMed ID: 16387509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The insulin-like growth factor (IGF) axis as an anticancer target in prostate cancer.
    Heidegger I; Massoner P; Sampson N; Klocker H
    Cancer Lett; 2015 Oct; 367(2):113-21. PubMed ID: 26231734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of epidermal growth factor receptor signaling by Saussurea involucrata, a rare traditional Chinese medicinal herb, in human hormone-resistant prostate cancer PC-3 cells.
    Way TD; Lee JC; Kuo DH; Fan LL; Huang CH; Lin HY; Shieh PC; Kuo PT; Liao CF; Liu H; Kao JY
    J Agric Food Chem; 2010 Mar; 58(6):3356-65. PubMed ID: 20166659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen and epidermal growth factor down-regulate cyclin-dependent kinase inhibitor p27Kip1 and costimulate proliferation of MDA PCa 2a and MDA PCa 2b prostate cancer cells.
    Ye D; Mendelsohn J; Fan Z
    Clin Cancer Res; 1999 Aug; 5(8):2171-7. PubMed ID: 10473102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment options in androgen-independent prostate cancer.
    Lara PN; Meyers FJ
    Cancer Invest; 1999; 17(2):137-44. PubMed ID: 10071598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the apoptosis pathway in prostate cancer.
    Zielinski RR; Eigl BJ; Chi KN
    Cancer J; 2013; 19(1):79-89. PubMed ID: 23337761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic modulation of prostate cancer metastasis.
    Krishna SN; Bergan RC
    Future Med Chem; 2014 Feb; 6(2):223-39. PubMed ID: 24467245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgens, androgen receptors, antiandrogens and the treatment of prostate cancer.
    Griffiths K; Morton MS; Nicholson RI
    Eur Urol; 1997; 32 Suppl 3():24-40. PubMed ID: 9267783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Designed modulation of sex steroid signaling inhibits telomerase activity and proliferation of human prostate cancer cells.
    Verma V; Sharma V; Singh V; Sharma S; Bishnoi AK; Chandra V; Maikhuri JP; Dwivedi A; Kumar A; Gupta G
    Toxicol Appl Pharmacol; 2014 Oct; 280(2):323-34. PubMed ID: 25123791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intracellular adaptor molecules and AR signalling in the tumour microenvironment.
    Reebye V; Frilling A; Habib NA; Mintz PJ
    Cell Signal; 2011 Jun; 23(6):1017-21. PubMed ID: 21130868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular pathology and prostate cancer therapeutics: from biology to bedside.
    Rodrigues DN; Butler LM; Estelles DL; de Bono JS
    J Pathol; 2014 Jan; 232(2):178-84. PubMed ID: 24108540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.